CAR T-Cell Therapy Associated Toxicities: Bijal Shah, MD, MS; Michael Wang, MD


The hematologists from Moffitt Cancer Center and The University of Texas MD Anderson Cancer Center discussed CAR T-associated toxicities.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, and Michael Wang, MD, professor, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, to learn more about the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

Shah and Wang discussed cytokine release syndrome (CRS) and neurotoxicity, which are unique toxicities commonly associated with CAR T-cell therapy in patients with hematologic malignancies. They also discussed infections that can arise with this treatment because CAR T-cell therapy is thought to enhance B-cell aplasia. This compromises cellular immunities and makes patients susceptible to potentially life-threatening infections, Wang explained. It is important to monitor patients with hematologic malignancies who receive CAR T-cell therapy for potential cardiac toxicities as well.

Although the toxicities associated with CAR T-cell therapy are broad, they are routinely seen in real-world clinical practice and require specialized management, Shah and Wang conclude.

Related Videos
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
Frederick “Eric” Arnold, PhD
David Porter, MD
Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.